Hypertension:收缩压和长期连续监测房颤筛查对卒中的影响

2022-07-10 MedSci原创 MedSci原创

ILR筛查房颤对血栓栓塞事件的益处随着血压的升高而增加。收缩压≥150mm Hg与≥24小时的房颤发作风险增加>1.5倍相关,同时通过ILR筛查将卒中或全身动脉栓塞的风险降低了近50%。

房颤可使卒中风险增加5倍,通过指南指导的口服抗凝治疗可有效降低卒中风险。植入心血管电子设备的患者大多数房颤发作是无症状的,即使是短暂的房颤发作也与卒中风险增加有关,其中高血压是众所周知的房颤危险因素,但缺乏关于收缩压与连续房颤筛查效果之间相互作用的数据。

近日,心血管权威杂志Hypertension上发表了一篇研究文章,LOOP研究将年龄在70至90岁且具有额外卒中风险因素的未患房颤个体随机分配至使用植入式循环记录器(ILR)进行筛查并在检测到房颤发作≥6分钟后开始抗凝治疗或常规治疗。

该研究总共有5997名具有基线收缩压测量值的参与者被纳入该子研究。研究人员使用特定原因Cox模型中的首次事件发生时间原则分析结局。

与对照组相比,ILR筛查的卒中或全身动脉栓塞的风险比随着收缩压的增加而降低。在收缩压≥150mmHg的参与者中,ILR筛查使卒中或全身动脉栓塞的风险降低了44%(调整后的风险比为0.56[0.37-0.83])。在ILR组中,收缩压≥150mmHg与24小时以上的房颤事件发生率高于收缩压较低的发生率相关(调整后的风险比为1.70[1.08-2.69]),但与房颤的总体发生率无关(调整后的P>0.05)。

由此可见,ILR筛查房颤对血栓栓塞事件的益处随着血压的升高而增加。收缩压≥150mm Hg与≥24小时的房颤发作风险增加>1.5倍相关,同时通过ILR筛查将卒中或全身动脉栓塞的风险降低了近50%。但是,这些结果应值得进一步研究。

原始出处:

Lucas Yixi Xing.et al.Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy).Hypertension.2022.https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.122.19333

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840382, encodeId=c7f6184038241, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Dec 25 16:27:30 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729660, encodeId=07601e2966084, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 05 16:27:30 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039328, encodeId=211b20393284c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Feb 19 12:27:30 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501591, encodeId=ab0e150159178, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593649, encodeId=62a31593649d4, content=<a href='/topic/show?id=0585542e5f3' target=_blank style='color:#2F92EE;'>#房颤筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54275, encryptionId=0585542e5f3, topicName=房颤筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ec518152182, createdName=medscijoin, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840382, encodeId=c7f6184038241, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Dec 25 16:27:30 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729660, encodeId=07601e2966084, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 05 16:27:30 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039328, encodeId=211b20393284c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Feb 19 12:27:30 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501591, encodeId=ab0e150159178, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593649, encodeId=62a31593649d4, content=<a href='/topic/show?id=0585542e5f3' target=_blank style='color:#2F92EE;'>#房颤筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54275, encryptionId=0585542e5f3, topicName=房颤筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ec518152182, createdName=medscijoin, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2023-04-05 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840382, encodeId=c7f6184038241, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Dec 25 16:27:30 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729660, encodeId=07601e2966084, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 05 16:27:30 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039328, encodeId=211b20393284c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Feb 19 12:27:30 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501591, encodeId=ab0e150159178, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593649, encodeId=62a31593649d4, content=<a href='/topic/show?id=0585542e5f3' target=_blank style='color:#2F92EE;'>#房颤筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54275, encryptionId=0585542e5f3, topicName=房颤筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ec518152182, createdName=medscijoin, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840382, encodeId=c7f6184038241, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Dec 25 16:27:30 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729660, encodeId=07601e2966084, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 05 16:27:30 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039328, encodeId=211b20393284c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Feb 19 12:27:30 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501591, encodeId=ab0e150159178, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593649, encodeId=62a31593649d4, content=<a href='/topic/show?id=0585542e5f3' target=_blank style='color:#2F92EE;'>#房颤筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54275, encryptionId=0585542e5f3, topicName=房颤筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ec518152182, createdName=medscijoin, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1840382, encodeId=c7f6184038241, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Dec 25 16:27:30 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729660, encodeId=07601e2966084, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 05 16:27:30 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039328, encodeId=211b20393284c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Feb 19 12:27:30 CST 2023, time=2023-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501591, encodeId=ab0e150159178, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593649, encodeId=62a31593649d4, content=<a href='/topic/show?id=0585542e5f3' target=_blank style='color:#2F92EE;'>#房颤筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54275, encryptionId=0585542e5f3, topicName=房颤筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ec518152182, createdName=medscijoin, createdTime=Tue Jul 12 06:27:30 CST 2022, time=2022-07-12, status=1, ipAttribution=)]

相关资讯

JCEM:糖尿病患者收缩压降低与血管结局之间的因果关系

收缩压降低与糖尿病CAD和肾病风险降低之间存在因果关系。这为终身控制收缩压在预防糖尿病相关血管预后方面的有益作用提供了遗传学证据。

JACC:同时考虑收缩压和舒张压,控制目标该如何定?

JACC:ALLHAT研究中收缩压和舒张压对心血管事件结果的贡献

JAHA:急性心力衰竭患者收缩压与结局的关系

SBP升高与AHF患者良好的短期和长期结局相关。在预先设定的亚组分析中,研究人员发现基线SBP与LVEF≥40%的患者死亡率无关,但与LVEF<40%患者的死亡率密切相关。

Stroke:收缩压变化轨迹与急性脑出血患者预后的相关性

收缩压从210mmHg以上降至140mmHg以下的急性脑出血患者3个月时的死亡或残疾和急性肾损伤的风险最高

BMC Medicine:超50万人的大数据表明,无论血压高低,男性患痴呆症风险都较高!

低血压和高血压都与男性患痴呆症的风险较高有关,但对女性而言,痴呆症的患病风险随血压升高而增加。

Alzheimers Dementia:收缩压越低,晚年的痴呆风险更低

未经降压药物治疗的低SBP与痴呆风险的显著降低和较少的Aβ有关。